FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2899258057> ?p ?o ?g. }

• W2899258057 endingPage "152" @default.
• W2899258057 startingPage "152" @default.
• W2899258057 abstract "Abstract Background: Dara, a human IgGκ monoclonal antibody that targets CD38, is approved in combination with bortezomib, melphalan, and prednisone (VMP) for the treatment of newly diagnosed (ND) MM. CyBorD is another commonly used immunomodulatory drug-sparing regimen for MM. We evaluated the safety and efficacy of dara-CyBorD and administered the first dara infusion as a split dose over 2 days in pts with NDMM or relapsed MM (RMM) after 1 prior line of therapy. Methods: This is an ongoing, multicenter, single-arm, open-label, phase 2 study conducted at US community oncology centers in pts aged ≥18 years with documented MM per IMWG criteria; measurable disease; ECOG performance score (PS) of 0-2; and ≤1 prior line of therapy. Pts received 4-8 cycles (C) of dara-CyBorD (oral cyclophosphamide 300 mg/m2 on Days 1, 8, 15, and 22; subcutaneous bortezomib 1.5 mg/m2 on Days 1, 8, and 15; and oral or IV dexamethasone 40 mg weekly) every 28 days. Dara was administered at 8 mg/kg IV in 500 ml on Days 1 and 2 of C1, 16 mg/kg weekly from C1D8 through C2, 16 mg/kg every 2 weeks (q2w) for C3-6, and 16 mg/kg q4w for C7-8. After induction, pts could undergo autologous stem cell transplantation (ASCT). All pts receive 12 cycles of maintenance dara 16 mg/kg IV q4w. The primary endpoint was the proportion of pts achieving very good partial response or better (VGPR+) after 4 induction cycles using a computer algorithm based upon IMWG response criteria. Results: A total of 101 (87 ND, 14 RMM) pts were enrolled; 100 (86 ND, 14 RMM) pts received at least 1 dose of study treatment. Median age was 63 years (63 ND, 68 RMM); most pts were white (81%), male (64%), had ECOG PS 0-1 (94%), and had IgG (57%) or IgA (17%) MM; 35% of pts had high-risk cytogenetics defined as del(17p), t(4:14), or t(14;16). Eighty-two ND pts completed at least 4 induction cycles, 55 at least 6 cycles, and 26 the maximum of 8 cycles; 28 ND pts underwent ASCT by the data cutoff date. After 4 induction cycles, 44% of ND pts achieved VGPR+ (5% CR) with an overall response rate (ORR) of 79%. The VGPR+ rate (57%), CR rate (14%), and ORR (71%) were similar in RMM pts. At the end of induction (median 6 cycles), the VGPR+ rate, CR rate, and ORR in ND pts were 56%, 9%, and 81%, respectively. With a median follow up of 7.9 months, median PFS and OS were not reached; the 12-month PFS and OS rates were 87% and 99%, respectively, in ND pts. All 100 evaluable pts experienced ≥1 treatment-emergent adverse event (AE). AEs with incidence ≥20% included fatigue, nausea, diarrhea, cough, insomnia, vomiting, constipation, upper respiratory tract infection, dyspnea, headache, and back pain. Grade ≥3 AEs were reported for 56% of pts; the most common (≥10%) was neutropenia. Serious AEs (SAEs) occurred in 21% of pts; the most common (≥2%) were atrial fibrillation, bacteremia, pulmonary embolism, and mental status changes. AEs led to permanent treatment discontinuation in 3% of pts. Infusion reactions (IRs) occurred in 54% of pts, including 49% at C1D1 and 4% at C1D2; 2 Grade 3 IRs (hypertension, anaphylactic reaction) occurred at C1D1; no Grade ≥4 IRs occurred. The most common (≥5%) IRs were chills, cough, dyspnea, nausea, pruritus, and flushing. Median infusion time was 4.5 hours for C1D1, 3.8 hours for C1D2, and 3.5 hours for subsequent doses. Conclusion: Dara-CyBorD was active and well tolerated in pts with ND and RMM, including pts with high-risk cytogenetics. ORR, VGPR+, and CR rates improved with cycles 5-8 of induction, indicating that longer therapy with dara results in deeper response. Preliminary PFS and OS data in ND pts in the first year are comparable to dara-VMP. The safety profile was consistent with that previously reported for dara, with no new safety signals observed. Split first daratumumab dosing was feasible, reduced Day 1 infusion time, and resulted in a similar IR rate as previously described for single-dose administration. These findings indicate that dara-CyBorD, using a split-dose first infusion, can be safely administered in the community setting and may be an effective treatment option for pts with MM. www.clinicaltrials.gov identifier: NCT02951819 Figure 1. Kaplan-Meier estimate of progression-free survival (PFS) among patients with newly diagnosed multiple myeloma. Disclosures Yimer: AstraZeneca: Speakers Bureau; Puma Biotechnology: Equity Ownership; Clovis Oncology: Equity Ownership; Celgene: Membership on an entity's Board of Directors or advisory committees; Seattle Genetics: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Epizyme: Equity Ownership; Janssen: Speakers Bureau. Melear:Janssen: Speakers Bureau. Faber:Amgen: Honoraria, Membership on an entity's Board of Directors or advisory committees; Genentech: Honoraria, Membership on an entity's Board of Directors or advisory committees; Cardinal Health: Honoraria, Membership on an entity's Board of Directors or advisory committees; Celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees. Bensinger:celgene: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Takeda: Speakers Bureau; amgen: Speakers Bureau; Janssen: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Burke:Gilead: Consultancy; Genentech: Consultancy; Celgene: Consultancy; Abbvie: Consultancy; Bayer: Consultancy; Seattle Genetics: Consultancy, Speakers Bureau; Tempus Labs: Consultancy. Narang:Janssen: Speakers Bureau; Celgene: Consultancy, Speakers Bureau. Stevens:Bayer: Consultancy, Membership on an entity's Board of Directors or advisory committees. Gunawardena:Janssen/ Johnson & Johnson: Employment, Equity Ownership. Lutska:Janssen/ Johnson & Johnson: Employment, Equity Ownership. Qi:Janssen/ Johnson & Johnson: Employment, Equity Ownership. Ukropec:Janssen Scientific Affairs, LLC: Employment. Qi:Janssen Research & Development, LLC: Employment. Lin:Janssen/ Johnson & Johnson: Employment, Equity Ownership. Rifkin:Amgen: Consultancy; McKesson: Equity Ownership; Boehringer Ingelheim: Consultancy; Celgene: Consultancy; EMD Serono: Consultancy; Takeda: Consultancy; Sandoz: Consultancy." @default.
• W2899258057 created "2018-11-09" @default.
• W2899258057 creator A5010388094 @default.
• W2899258057 creator A5014136878 @default.
• W2899258057 creator A5018302007 @default.
• W2899258057 creator A5024431512 @default.
• W2899258057 creator A5026806277 @default.
• W2899258057 creator A5030896087 @default.
• W2899258057 creator A5035594574 @default.
• W2899258057 creator A5037878488 @default.
• W2899258057 creator A5043351209 @default.
• W2899258057 creator A5047540200 @default.
• W2899258057 creator A5061916244 @default.
• W2899258057 creator A5071375525 @default.
• W2899258057 creator A5086470642 @default.
• W2899258057 creator A5091600784 @default.
• W2899258057 date "2018-11-29" @default.
• W2899258057 modified "2023-09-27" @default.
• W2899258057 title "Lyra: A Phase 2 Study of Daratumumab (Dara) Plus Cyclophosphamide, Bortezomib, and Dexamethasone (Cybord) in Newly Diagnosed and Relapsed Patients (Pts) with Multiple Myeloma (MM)" @default.
• W2899258057 doi "https://doi.org/10.1182/blood-2018-152" @default.
• W2899258057 hasPublicationYear "2018" @default.
• W2899258057 type Work @default.
• W2899258057 sameAs 2899258057 @default.
• W2899258057 citedByCount "9" @default.
• W2899258057 countsByYear W28992580572019 @default.
• W2899258057 countsByYear W28992580572020 @default.
• W2899258057 countsByYear W28992580572021 @default.
• W2899258057 countsByYear W28992580572022 @default.
• W2899258057 countsByYear W28992580572023 @default.
• W2899258057 crossrefType "journal-article" @default.
• W2899258057 hasAuthorship W2899258057A5010388094 @default.
• W2899258057 hasAuthorship W2899258057A5014136878 @default.
• W2899258057 hasAuthorship W2899258057A5018302007 @default.
• W2899258057 hasAuthorship W2899258057A5024431512 @default.
• W2899258057 hasAuthorship W2899258057A5026806277 @default.
• W2899258057 hasAuthorship W2899258057A5030896087 @default.
• W2899258057 hasAuthorship W2899258057A5035594574 @default.
• W2899258057 hasAuthorship W2899258057A5037878488 @default.
• W2899258057 hasAuthorship W2899258057A5043351209 @default.
• W2899258057 hasAuthorship W2899258057A5047540200 @default.
• W2899258057 hasAuthorship W2899258057A5061916244 @default.
• W2899258057 hasAuthorship W2899258057A5071375525 @default.
• W2899258057 hasAuthorship W2899258057A5086470642 @default.
• W2899258057 hasAuthorship W2899258057A5091600784 @default.
• W2899258057 hasConcept C126322002 @default.
• W2899258057 hasConcept C141071460 @default.
• W2899258057 hasConcept C159654299 @default.
• W2899258057 hasConcept C203014093 @default.
• W2899258057 hasConcept C2776063141 @default.
• W2899258057 hasConcept C2776364478 @default.
• W2899258057 hasConcept C2776694085 @default.
• W2899258057 hasConcept C2776755627 @default.
• W2899258057 hasConcept C2777478702 @default.
• W2899258057 hasConcept C2778684742 @default.
• W2899258057 hasConcept C2778822529 @default.
• W2899258057 hasConcept C2779050716 @default.
• W2899258057 hasConcept C2779551797 @default.
• W2899258057 hasConcept C2780401358 @default.
• W2899258057 hasConcept C2781119759 @default.
• W2899258057 hasConcept C2781413609 @default.
• W2899258057 hasConcept C2911091166 @default.
• W2899258057 hasConcept C36394416 @default.
• W2899258057 hasConcept C71924100 @default.
• W2899258057 hasConcept C90924648 @default.
• W2899258057 hasConceptScore W2899258057C126322002 @default.
• W2899258057 hasConceptScore W2899258057C141071460 @default.
• W2899258057 hasConceptScore W2899258057C159654299 @default.
• W2899258057 hasConceptScore W2899258057C203014093 @default.
• W2899258057 hasConceptScore W2899258057C2776063141 @default.
• W2899258057 hasConceptScore W2899258057C2776364478 @default.
• W2899258057 hasConceptScore W2899258057C2776694085 @default.
• W2899258057 hasConceptScore W2899258057C2776755627 @default.
• W2899258057 hasConceptScore W2899258057C2777478702 @default.
• W2899258057 hasConceptScore W2899258057C2778684742 @default.
• W2899258057 hasConceptScore W2899258057C2778822529 @default.
• W2899258057 hasConceptScore W2899258057C2779050716 @default.
• W2899258057 hasConceptScore W2899258057C2779551797 @default.
• W2899258057 hasConceptScore W2899258057C2780401358 @default.
• W2899258057 hasConceptScore W2899258057C2781119759 @default.
• W2899258057 hasConceptScore W2899258057C2781413609 @default.
• W2899258057 hasConceptScore W2899258057C2911091166 @default.
• W2899258057 hasConceptScore W2899258057C36394416 @default.
• W2899258057 hasConceptScore W2899258057C71924100 @default.
• W2899258057 hasConceptScore W2899258057C90924648 @default.
• W2899258057 hasIssue "Supplement 1" @default.
• W2899258057 hasLocation W28992580571 @default.
• W2899258057 hasOpenAccess W2899258057 @default.
• W2899258057 hasPrimaryLocation W28992580571 @default.
• W2899258057 hasRelatedWork W2025081120 @default.
• W2899258057 hasRelatedWork W2258102812 @default.
• W2899258057 hasRelatedWork W2292288256 @default.
• W2899258057 hasRelatedWork W2513226303 @default.
• W2899258057 hasRelatedWork W2546436011 @default.
• W2899258057 hasRelatedWork W2899258057 @default.
• W2899258057 hasRelatedWork W2981018427 @default.
• W2899258057 hasRelatedWork W3127479238 @default.
• W2899258057 hasRelatedWork W3197023233 @default.
• W2899258057 hasRelatedWork W4310161894 @default.

• next